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More than 27 million Americans undergo noncardiac surgery annually. Cardiac complications can be
a major source of morbidity and mortality in the perioperative period. Preoperative risk stratiﬁcation,
intraoperative ischemia monitoring and postoperative surveillance help to predict, identify and efﬁ-
ciently treat these adverse events. A renewed emphasis on preoperative evaluation has helped to identify
patients at an increased risk for adverse cardiac events and thus, implement noninvasive or invasive
cardio protective strategies in an attempt to minimize these complications. In this review we brieﬂy
describe the current evidence on perioperative management of patients presenting for noncardiac
surgery. As the surgeon will remain one of the ﬁrst to evaluate patients before noncardiac surgery it is
essential he/she be well versed with this information.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Magnitude of the problem and the need for risk
stratiﬁcation
Most of the data regarding the incidence of perioperative
cardiac events was collected in the 1980’s and 1990’s, before cardiac
speciﬁc biomarkers became available. Major adverse cardiac events
(ACE’s) were found to occur in 2% of relatively unselected patients
(not limited to patients with a known risk for coronary artery
disease) undergoing noncardiac surgery (NCS)1 to up to 34% in high
risk patients. Observations, from recent placebo-controlled trials
evaluating the efﬁcacy of perioperative pharmacological interven-
tions e.g. in the Metoprolol after Vascular Surgery (MaVS) study,
ACE’s were found to occur in 11.9%, 11.1%, 12.0% and 33.3% of the
patients in the placebo group with 1, 2, 3 and 4 preoperative risk
factors, respectively.2 Similarly Poldermans et al3 reported a 34%
incidence of ACE’s in high risk patients. Inspite of advancement in
perioperative medicine this similar incidence of adverse post-
operative cardiac events, over the years, can be attributed to an
increasing number of elderly patients presenting for more invasive
diagnostic and complex surgical procedures.4
It is projected that by 2030, there will be 71 million Americans
older than 65 years.5 This is the largest growing population cohortlno1@hfhs.org (V.Velanovich),
ciates Ltd. Published by Elsevier Ltpresenting for surgery. As the prevalence of chronic disease condi-
tions including cardiovascular disease, cerebrovascular disease and
diabetes increases with age6 and 25% of surgical procedures per-
formed in this elderly population, today, come under the category of
high to intermediate risk, therewill be adisproportionate increase in
the number of patients at risk for perioperative ACE’s.2. Perioperative cardiac events and impact on health care
In a cohort of 3790 patients undergoing NCS Fleischmann et al7
found that cardiac complications increased mean length of hospital
stay by 11 days. Patients experiencing a myocardial infarction (MI)
or cardiac arrest after NCS are known to have increasedmortality in
hospital and following discharge.8e11 In total, perioperative ACE’s
and their consequent outcomes cause an astounding increase in
health care costs of up to 20 billion per year.12
The impact of routine preoperative testing, on health care cannot
be ignored. Asymptomatic patients with or without clinical risk
factors are subjected to the so called “cardiac clearance”. Auerbachet
al13 in an observation study of American Society of Anesthesiology
(ASA) 4 andhigher physical status patients presenting forNCS found
inconsistent effects of specialist consultations on the quality of care.
Delay in surgeryas a result of testing increaseshospital lengthof stay
and also mortality after discharge.14 Adherence to published peri-
operative screening guidelines has been shown to signiﬁcantly
reduce the cost of patient care.15d. All rights reserved.
Table 2
Active Cardiac Conditions for Which the Patient should undergo Evaluation and




Unstable or severe angina
Recent MI (7e30days)
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The goal of preoperative risk assessment is to identify patient
and procedure factors that increase the risk for perioperative ACE’s.
These can be divided into following three broad but interrelated
categories:Decompensated HF NYHA functional class IV; worsening or
new-onset HF
Signiﬁcant arrhythmias High-grade atrioventricular block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias
(including atrial ﬁbrillation) with uncontrolled
ventricular rate (HR greater than 100 bpm at rest)
Symptomatic bradycardia
Newly recognized ventricular tachycardia
Severe valvular disease Severe aortic stenosis (mean pressure gradient
greater than 40 mm Hg, aortic valve area
less than 1.0 cm2, or symptomatic)
Symptomatic mitral stenosis (progressive dyspnea
on exertion, exertional presyncope, or HF)3.1. Surgery related risk factors
Need for emergent surgery, surgery speciﬁc factors (e.g. ﬂuid
shifts, blood loss, duration, laparoscopic or endovascular), and
prevalence of co-morbidities known to be associated with certain
surgical conditions, determine the risk associated with various
surgical procedures. Based on this, noncardiac surgical procedures
are classiﬁed as vascular, intermediate risk and low risk by the
American College of Cardiology/American Heart Association (ACC/
AHA) for the purpose of risk stratiﬁcation. (Table 1).16
Patients presenting with emergent, sometimes, life- threatening
conditions (Table 2), are at a 2e5 times increased risk of cardiac
complications.17e19 Lack of opportunity for adequate preoperative
preparation and patient presentation in decompensated disease
states contribute to the higher risk of cardiac complications in such
situations. For elective NCS the nature and extent of the surgery
determines risk for cardiac complication independent of overt
clinical risk factors and patients functional status.20 Many patients
presenting for vascular surgery have risk factors for coronary artery
disease (hypertension, diabetes mellitus, tobacco use, and hyper-
lipidemia), in addition to, asymptomatic, underlying coronary
artery disease CAD).21 The increased prevalence of CAD, complexity
of open vascular procedures (ﬂuid shifts, hemodynamic ﬂuctua-
tions), and postoperative thrombogenicity increase the risk of
postoperative cardiac complications in these patients.19
The emerging evidence in support of decrease perioperative
mortality in patients undergoing endovascular aortic aneurysm
repair deserves special mention. As demonstrated by the DREAM
(Dutch Randomized Endovascular Aneurysm Management)22 trial
and EVAR (Endovascular Abdominal aortic aneurysm Repair)-1
trial23e25 30-day mortality was lower in the endovascular repair
group, but on 2 year follow-up cumulative survival was not found
to be signiﬁcantly different. Endovascular abdominal aortic aneu-
rysm repair has been classiﬁed as an intermediate risk surgery, but
long-term mortality should be taken into consideration during risk
stratiﬁcation.
Intermediate risk procedures cover a wide variety of surgical
procedures and carry a 1% to 5% risk of ACE’s. Location and extent of
surgical procedure are important determinants of perioperative
ACE’s e.g. intrathoracic surgery for pulmonary neoplasm carries
a relatively higher risk of ACE’s than laparoscopic intraperitoneal
surgery.16,20,26Table 1
Cardiac Risk Stratiﬁcation for Noncardiac Surgical Procedures.16
Risk Stratiﬁcation Procedure Examples
Vascular (reported cardiac
risk often more than 5%)




Intraperitoneal and intrathoracic surgery
Carotid endarterectomy
Head and neck surgery
Orthopedic surgery
Prostate surgery
Low (reported cardiac risk





Ambulatory surgeryPatients undergoing endoscopic procedures, cataract surgery
and other ambulatory surgeries come under the low risk category.
Warner et al27 determined the incidence of perioperative MI to be
0.03% in 38,500 patients who underwent 45,090 consecutive
ambulatory procedures involving general and local anesthesia
techniques. As recommended by the ACC/AHA in 2007 patients
undergoing such low risk procedures can proceed with surgery
without further cardiac evaluation.3.2. Patient related risk factors
A carefully conducted clinical evaluation based on history,
physical examination, review of the electrocardiogram (ECG), and
in certain situations review of echocardiographic ﬁndings provides
adequate information to identify risk factors predictive of peri-
operative ACE’s. The ﬁnding of active cardiac conditions (Table 2),
demands delay in NCS, further evaluation, and management of
these cardiac condition unless surgery is deemed emergent.
In patients undergoing NCS, various cardiac risk scoring systems
to delineate perioperative cardiac risk have been investigated.28e30
The multivariable, Revised Cardiac Risk Index (RCRI), developed by
Lee et al, in 1999, is the one most widely used today.1 Major ACE’s
are known to occur in 0.4%, 0.9%, 7%, and 11% in patients with 0,1, 2,
and 3 risk factors. In 2007 when the ACC/AHA published guidelines
for perioperative cardiovascular evaluation and care for NCS, clin-
ical, patient related risk factors were derived from the RCRI.
(Table 3)3.3. Patient’s functional status
Determining the patient’s functional capacity or exercise toler-
ance is a pivotal factor in risk assessment.16 Self reported, limited,
exercise tolerance has been shown to correlate with postoperative
complications.31 Functional status is most commonly estimated
from the ability to perform tasks of daily living and expressed as
metabolic equivalents (MET) of oxygen consumption. (One MET is
deﬁned as the resting oxygen consumption of a 70 kg, 40 year old
male¼ 3.5 ml/kg/min).32 Patients who are able to meet a 4 MET
demand during activity have enough reserve to increase oxygen
delivery and meet heightened oxygen requirements in the peri-
operative period.31 They should be able to proceed with planned
surgery without any further testing or medical interventions. On
the other hand management of patients who have unknown or
Table 3
Clinical Risk Factors That Predict Risk of Cardiac Death and Nonfatal Myocardial
Infarction at Time of Noncardiac Surgery.16
Clinical Risk Factor Examples
History of ischemic heart Previous myocardial infarction disease




Previous PCI or CABG
History of compensated




Evidence of heart failure
on chest radiograph
History of cerebrovascular Previous TIA disease
Previous stroke
Diabetes mellitus With or without preoperative
insulin therapy
Renal insufﬁciency Creatinine level >2 mg/dL
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has been an area of intense research.4. Practice guidelines on perioperative cardiovascular
evaluation and care for noncardiac surgery
In 1996 the ACC/AHA published a consensus statement on the
preoperative cardiac evaluation of patients presenting for NCS.
These guidelines were revised in 2001 and extensively revised later
in 2007. Throughout these revisions the basic algorithmic approach
of risk stratiﬁcation has remained the same, highlighting the
interplay between nature and circumstance of surgery, patient’s co
morbidities and functional capacity. In 2009 the ACC/AHA repub-
lished the 2007 guidelines after incorporating the 2009 American
College of Cardiology Foundation (ACCF)/AHA Focused Update on
Perioperative Beta Blockers into the original document.33,34 The
ACC/AHA has segregated these guidelines into three categories
based on the available level of evidence (Table 4)
The current algorithm delineates 5 key steps in the preoperative
cardiac evaluation of patients presenting for NCS and is illustrated
in Fig. 1. Following a similar algorithmic and step wise approach to
evaluation and optimization of patients presenting for noncardiac
surgery, the European Society of Cardiology (ESC) published
guidelines for preoperative cardiac risk assessment and perioper-
ative cardiac management in non cardiac surgery in 2010.35 (The
interested reader is referred to the ACC/AHA and ESC websites
where complete versions of these documents are available).5. Cardiac stress testing: role in risk stratiﬁcation and therapy
Exercise ECG is a low cost method, of detecting inducible
ischemia and provides objective measurement of functional
capacity. Themean sensitivity and speciﬁcity of exercise ECG testing
for the detection of underlying CAD has been found to be 68% andTable 4
ACC/AHA guideline classiﬁcation scheme.16
Class Level of Evidence
Class I Beneﬁt outweighs the risk and the procedure/treatment
should be performed/administered
Class IIa Evidence is equivocal but it is reasonable that the
procedure/treatment be performed/administered
Class IIb Evidence is equivocal but the procedure/treatment may be
performed/administered
Class III Risk outweighs the beneﬁt and the procedure/treatment should not
be performed/administered77% respectively with a predictive accuracy of 73%.36,37 Due to
exercise limitation secondary to peripheral artery disease, degen-
erative joint disease or poor pulmonary reserve, 30e60% of patients
referred for preoperative exercise cardiac evaluation are unable to
undergo adequate testing.38,39 As a result pharmacological testing
using myocardial perfusion imaging (MPI) or dobutamine stress
echocardiography (DSE) are used to detect inducible ischemia
preoperatively.
MPI is performed at rest and during vasodilator stress, to detect
adequate coronary vasodilator reserve, reversible perfusion defects
(myocardium at risk) or ﬁxed perfusion defects (scarred myocar-
dium). Reversible perfusion defects are associated with a higher
risk of ACE’s.40 DSE, involves evaluation of ventricle wall motion
initially at rest and then during a dobutamine stress. Although
superior to MPI the positive predictive value of DSE for cardiac
death and MI still remains low, 17% and 26% respectively.41e43
Further testing prompted by such positive results may lead to
unnecessary coronary angiography, increased costs and delay in
surgery. Negative predicative value of a normal cardiac stress test
by both MPI and DSE has been found to be approximately 99%.16
6. Perioperative management: revascularization strategies
As the focus of perioperative care of patients presenting for NCS
shifts from risk stratiﬁcation to risk management, surgical, and in
particular, medical strategies are becoming an integral part of peri-
operative evaluation. Two recent landmark prospective studies, the
CARP (Coronary Artery Revascularization Prophylaxis) randomized
trial44 and DECREASE (Dutch Echocardiographic Cardiac Risk Evalua-
tion Applying Stress Echo)-V pilot study45 have failed to show any
survival beneﬁt with preoperative coronary revascularization. In the
CARP trial 510patientsundergoing vascular surgerywere randomized
to coronary artery revascularization (258) before surgery or no coro-
nary revascularization before surgery (252). Patients with left main
CAD of >50%, left ventricle ejection fraction of less than 20%, and
severe aortic stenosis were excluded from the trial. These exclusion
criteria later became one of the biggest criticisms of the CARP trial as
patients who probably would have beneﬁtedmost from preoperative
revascularization were not enrolled. Medical management with
beta blockers, antiplatelet agents, angiotensin-convertinge enzyme
inhibitors, and statins were continued, throughout the follow-up
period and was attributed to have negated any survival beneﬁt of
preoperative revascularization. The DECREASE-V pilot study, which
proved to be an opposite extreme of the CARP trial, enrolled 101
patients with 3 or more clinical risk factors and extensive stress
induced ischemia. Patients were strictly randomized to revasculari-
zation either by CABG or PCI (even those with coronary anatomy/
condition unsuitable to revascularization) or no revascularization.
b-blockers and dual antiplatelet therapy was continued in the peri-
operative period in patients who underwent PCI. Not only did the
DECREASE-V pilot study fail to demonstrate any beneﬁt of prophy-
lactic coronary revascularization inhigh riskpatients, 30-dayall cause
mortality was double in the revascularization group when compared
to the control group. In both these studies intensive medical
management in particular b-blockers, which favorably inﬂuence the
oxygen supply-demand of the cardiac muscle and provide protection
against plaque rupture, has been postulated to have eliminated any
survival beneﬁt provided by coronary revascularization.
Both of these trials were conducted in patients undergoing high
risk vascular surgery. The CARP trial enrolled relatively low risk
patients and theDECREASE-Vpilot studyenrolled signiﬁcantly higher
risk patients. The extent to which results of these RCT can be extrap-
olated outside the setting of vascular surgery can only be speculated
but it does seem reasonable to do so. Even amongst patients under-
going vascular surgery the results of these studies should be
Emergency noncardiac surgery 
Active Cardiac Conditions (table 
II)  
Low Risk Surgery 




Proceed with surgery with 
Perioperative ischemia 
surveillance and postoperative 
risk management (Class I) 
Evaluate and treat active 
condition (Class I) 
Proceed with surgery with no 





Proceed with surgery with no 
further evaluation. (Class I) 
No or 
unknown 
Determine clinical risk factors  
3 or more risk factors 1-2 risk factors 
Intermediate risk 
surgery
Vascular Surgery Vascular Surgery
Proceed with surgery and consider 
1.  HR control (class IIa) or 
2. Noninvasive cardiac testing (class IIb)
Consider testing if results will change 
management (Class IIa)
None Proceed with surgery with no 
further evaluation. (Class I)
≥
Fig. 1. American College of Cardiology (ACC)/American Heart Association (2009) algorithm for cardiac evaluation and care of patients presenting for noncardiac surgery.16
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Affairs medical centers across the United States were enrolled while
the DECREASEeV study was conducted in 6 different countries.
Although practice parameters and data collection can be controlled,
genetic variabilitywill alwaysbeaconcerndifﬁcult to eliminateunless
studies in speciﬁc population groups are undertaken.
One of the main objectives of preoperative cardiac evaluation
should be the identiﬁcation of patients with high risk coronary
anatomy, amenable to coronary revascularization, by the utilization
of appropriate noninvasive or invasive cardiac evaluation. Once
identiﬁed the next question that needs to be answered is “what the
best revascularization strategy would be, CABG or PCI?” In a core
review of preoperative coronary revascularization in patients
undergoing vascular surgery Kertai46 has critically analyzed recent
evidence on this subject. Long term outcomes appear to be better in
patients undergoing coronary artery bypass grafting (CABG) when
compared to percutaneous coronary intervention (PCI), but incom-
plete revascularization after PCI, impact of stent related complica-
tions and progressive occlusive coronary disease should be
considered while evaluating the disadvantages of PCI over CABG.47
Soon after undergoing PCI with or without intracoronary
stenting, a small but signiﬁcant fraction of patients present for NCS.
The heightened thrombogenic potential of newly implanted stents
and prothrombotic state induced by the surgical stress; increases
the risk of in stent thrombosis.19,48 Premature discontinuation of
antiplatelet therapy in patients with bare metal stents (BMS) ordrug eluting stent (DES) is associated with a high rate of stent
thrombosis and perioperative mortality.49e53 In 2007 the AHA/
ACC/Society for Cardiovascular Angiography and Interventions
(SCAI)/American College of Surgeons (ACS) issued a scientiﬁc
advisory recommending continuation of dual antiplatelet therapy
for a minimum of 4e6 weeks in patients with BMS and 12 months
in patients with DES.54 Similar recommendations were published
in the 2007 ACC/AHA guidelines on perioperative cardiovascular
evaluation and care for NCS16 and by the ASA in 2009.55 Elective
surgical procedures that carry a potential for increased perioper-
ative bleeding should be postponed until a minimum course of dual
antiplatelet therapy has been completed. In patients presenting for
emergency NCS soon after coronary stent placement due consid-
eration should be given to the risk of interrupting thienopyridine
therapy compared with the risk of bleeding from surgical proce-
dures, continuation of aspirin in the perioperative period and
restarting thienopyridine as soon as possible.
7. Perioperative management: medical strategies
7.1. b-blockers
In the latter half of the 1990’s two RCT enrolling a total of 312
patients’ demonstrated decreased cardiovascular morbidity and
mortality in patients treated with b-blockers.3,56. Over the next
decade several investigators looked at the efﬁcacy and safety of
V. Arora et al. / International Journal of Surgery 9 (2011) 23e28 27b-blockers in the perioperative period. The ACC/AHA published
recommendations for perioperative b-blockers in 2007 and recently
impelledby the Perioperative Ischemia Evaluation (POISE) trial ACCF/
AHA released a focused update on perioperative b-blockers.33,57 The
POISE trial was a large randomized control trial of ﬁxed dose
b-blockersenrollingover8000patients.Anybeneﬁtofb-blockerswas
offset by increased riskof strokeandmortality in the treatmentgroup.
Currently, the only class 1 indication is the continuation of b-blockers
inpatients already receivingb- blockers. Although b- blockers are still
recommended in patients with known ischemic heart disease or
congestive heart disease (CHD) undergoing vascular surgery or those
withmore than 1 risk factor undergoing vascular or intermediate risk
surgery further RCT’s are warranted to better determine their role in
these scenarios. The guidelines are uncertain about the use of
b-blockers in patients with only 1 clinical risk factor undergoing
vascular or intermediate risk surgery.16 Based on this paucity of data
many experts have urged careful interpretation of the current
guidelines and have advised not to use perioperative b-blockade as
a performance measure.58,59 Wherever indicated b- blockers should
be started days toweeks before surgery, titrated to a target heart rate
in anattempt to avoidperioperative hypotensionandbradycardia.3,60
7.2. Statins
Perioperative statin therapy has been shown to reduce the risk
adverse perioperative cardiac, major vascular, cerebrovascular
events, shorten length of hospital stay, have renal protective
effects,61 and improve overall long-term survival.62,63 Through
their non-lipid lowering pleiotropic effects, statins help prevent
perioperative MI.64 The ACC/AHA in their 2007 guidelines do
recommend the continuation of stains in the perioperative period
in patients already taking statins. Although more compelling
evidence clarifying the stance of perioperative statin therapy is
eagerly awaited, because of their low risk proﬁle in the perioper-
ative period65 and the increased mortality associated with acute
withdrawal of statin therapy,66 it is prudent to consider the inclu-
sion and maintenance of statin therapy in the perioperative period.
8. Conclusion and Future Directives
As the population continues to age identiﬁcation of the “at risk”
patient and prevention of perioperative ischemia during non
cardiac surgery continues to be a challenge. The approach to this
challenge has evolved from risk stratiﬁcation based on cardiac
testing to clinical risk stratiﬁcation and from risk stratiﬁcation to
risk management through perioperative medical strategies. When
the need for surgery is established it is essential to determine the
patients’ perioperative cardiovascular risk. One of the key elements
in determining this risk is a thorough yet focused history and
physical examination to identify active cardiac conditions and the
patient’s functional status. This information has to be integrated
with the risk associated with the planned surgical procedure. The
surgeon will more than often be the ﬁrst one to obtain this infor-
mation and is compelled to initiate appropriate management
instead of subjecting all patients with limited functional capacity or
those undergoing complex, high risk procedures to extensive
cardiac workup and evaluation. This also allows more timely and
effective management of limited health care resources.
Much progress has been made over the last decade and half
regarding themanagement of patients presenting for NCS butmany
questions still remained unanswered. Recent data has cast doubt on
the role of preoperative pharmacological interventions, inparticular
the role of b- blockers. Dosage should be titrated overweeks and not
just days to achieve a target heart rate while avoiding hypotension
and bradycardia. It is yet to be determined if one b antagonist issuperior to another. In view of the current evidence statin therapy
should be started as soon as possible and continued throughout the
perioperative period. Physicians should be wary of the fact that
sudden withdrawal of statin therapy can increase the risk of ACE’s.
In patients whom preoperative revascularization is indicated,
consensus on the timing and best strategy for revascularization is
still awaited. In the surgical patient with recently implanted coro-
nary stents, the risks and beneﬁts of stopping dual antiplatelet
therapy versus delaying the procedure have to be duly considered. A
multidisciplinary approach should be taken from the beginning with
close cooperation between the surgeon, cardiologist and anesthesi-
ologist. Due to increased thrombogenicity, current guidelines
recommend continuation of dual antiplatelet therapy for aminimum
of 4e6 weeks and 12 months in patients with BMS and DES,
respectively. Management of antiplatelet therapy after this “high
risk” period for stent thrombosis is yet to be determined. Aswe learn
more about these perioperative events it is essential for all members
of the perioperative team to be aware of perioperative evaluation
strategies with equal emphasis on what might be beneﬁcial and
what might be ineffective or even detrimental to patient care.
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